Get notified when SBEV files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — The auditor's going-concern opinion signals the company may not survive without new financing.
  • Material Weakness (new) — The company discloses material weaknesses in internal control over financial reporting, which could lead to inaccurate financial statements.
  • Nyse American Delisting Risk (new) — The company is out of compliance with NYSE American's stockholders' equity requirement, with negative equity of $15.3 million, and faces delisting if not remedied by January 29, 2027.
  • Customer Concentration and Loss (new) — The company's only recent revenue came from a single tequila customer that has terminated its contract, leaving no ongoing beverage revenue.
  • Cannepil Sales Decline (new) — Sales of the licensed product CannEpil have collapsed from $4.26 million in 2023 to under $100,000 in 2026, raising doubts about commercial viability.
  • Dilution From Convertible Preferred Stock and Warrants (new) — Outstanding preferred stock is convertible into over 11 million common shares, and warrants and options add further potential dilution, significantly reducing existing shareholders' ownership.
NYSE: SBEV Endovia Health Sciences, Inc. 424B3

Endovia Health Sciences registers resale of 5M shares by selling stockholder; company may receive up to $30.8M from ELOC

Filed August 28, 2026 · ~2 min read

Key Changes

  • high

    This is a secondary offering: selling stockholder C/M Capital Master Fund may resell up to 5,000,000 shares; Endovia receives no proceeds from those sales.

    The Offering verify on EDGAR →
  • high

    Endovia may receive up to $30,782,793 in gross proceeds from future sales of shares to C/M under the equity line of credit (ELOC), but the amount is not guaranteed.

    Use of Proceeds verify on EDGAR →
  • high

    The company reported a GAAP net loss of $25.2 million for 2025, including $14.2 million of non-cash items.

    Risk Factors verify on EDGAR →

5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

Partner

Trade SBEV commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify